5-year correlative analysis of ATEMPT: adjuvant T-DM1 vs paclitaxel+trastuzumab for stage I HER2+ BC

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

T-DM1 Vs. Trastuzumab as Adjuvant Therapy for HER2-Positive Breast CancerПодробнее

Dr. Sara Tolaney on Adjuvant T-DM1 Vs Paclitaxel and Trastuzumab for Stage I HER2+ Breast CancerПодробнее

Patient Perspectives on T-DM1 vs Paclitaxel/Trastuzumab for HER2+ Early Breast CancerПодробнее

Adjuvant T-DM1 for Stage I HER2+ Breast CancerПодробнее

Sara Tolaney, SABCS 2022: Adjuvant paclitaxel and trastuzumab for node-negative HER2+ breast cancerПодробнее

New Data Comparing Adjuvant T-DM1 vs Trastuzumab for HER2+ Breast CancerПодробнее

APT: adjuvant paclitaxel and trastuzumab for node-negative, HER2+ breast cancerПодробнее

T-DM1 as part of our standard of care with residual HER 2+ diseaseПодробнее

HER2-Targeted TherapiesПодробнее

Adjuvant T-DM1 for HER 2+ Breast Cancer: Critical Data From The KATHERINE StudyПодробнее

Phase 3 Trial Investigates T-DM1 and Pertuzumab in HER2+ Breast CancerПодробнее

Adjuvant treatment for stage I HER2+ breast cancerПодробнее

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancerПодробнее

Dr. Louis Weiner on the T-DM1 Mechanism of Action in HER2-Positive Breast CancerПодробнее

Early-Stage HER2+ Breast Cancer: The ATEMPT TrialПодробнее

Case Review: T-DM1 for Residual HER2+ Breast CancerПодробнее

Adjuvant T-DM1 Therapy for Early-Stage HER2+ Breast CancerПодробнее